DINAMIQS Opens State-of-the-Art cGMP Facility for Viral Vectors

DINAMIQS, a division of Siegfried AG, has launched a cutting-edge cGMP manufacturing facility for viral vectors in Zurich, marking the first of its kind facility in Switzerland. This new site provides comprehensive capabilities for the production of viral vector gene therapies, covering every stage from molecule design to the aseptic filling of drug products. With laboratory space operational since Q3 2024, Siegfried is enhancing its position within the expanding cell and gene therapy sector.

Located in the Bio-Technopark, this 2,500m² facility incorporates R&D, clinical, and commercial manufacturing under a single roof with a production scale of up to 1,000L. Its modular design and advanced single-use technologies ensure stringent containment and compliance with GMP standards. Additionally, DINAMIQS has partnered with SEAL Therapeutics to develop gene therapy for muscular dystrophy, capitalizing on the new facility's capabilities.